Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum

Australas J Dermatol. 2024 Jun;65(4):e111-e113. doi: 10.1111/ajd.14266. Epub 2024 Apr 10.
No abstract available

Keywords: brodalumab; hidradenitis suppurativa; paradoxical reaction; psoriasis; pyoderma gangrenosum.

Publication types

  • Letter
  • Case Reports

MeSH terms

  • Adalimumab* / adverse effects
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use
  • Drug Substitution
  • Female
  • Humans
  • Male
  • Middle Aged
  • Psoriasis / drug therapy
  • Pyoderma Gangrenosum* / chemically induced
  • Pyoderma Gangrenosum* / drug therapy

Substances

  • Adalimumab
  • Antibodies, Monoclonal, Humanized
  • brodalumab
  • Dermatologic Agents